Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change | Zendy

Anja Soldan | Zendy; Corinne Pettigrew | Zendy; Qing Cai | Zendy; MeiCheng Wang | Zendy; Abhay Moghekar | Zendy; Richard O’Brien | Zendy; Ola A. Selnes | Zendy; Marilyn Albert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change

Author(s) -

Anja Soldan,

Corinne Pettigrew,

Qing Cai,

MeiCheng Wang,

Abhay Moghekar,

Richard O’Brien,

Ola A. Selnes,

Marilyn Albert

Publication year - 2016

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2016.0194

Subject(s) - cognition , dementia , psychology , recall , alzheimer's disease , cognitive decline , audiology , effects of sleep deprivation on cognitive performance , disease , medicine , biomarker , oncology , psychiatry , cognitive psychology , biochemistry , chemistry

Clinical trials testing treatments for Alzheimer disease (AD) are increasingly focused on cognitively normal individuals in the preclinical phase of the disease. To optimize observing a treatment effect, such trials need to enroll cognitively normal individuals likely to show cognitive decline over the duration of the trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research